{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:46:31Z","timestamp":1793533591592,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R21HD092934"],"award-info":[{"award-number":["R21HD092934"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Perinatology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1053\/j.semperi.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T11:13:52Z","timestamp":1557486832000},"page":"375-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity"],"prefix":"10.1053","volume":"43","author":[{"given":"Deborah K.","family":"VanderVeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule U.","family":"Cataltepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1053\/j.semperi.2019.05.011_bib0001","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"issue":"8733","key":"10.1053\/j.semperi.2019.05.011_bib0002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0140-6736(91)90742-8","article-title":"Retinopathy of prematurity","volume":"337","author":"Hellstr\u00f6m","year":"1991","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1053\/j.semperi.2019.05.011_bib0003","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on m\u00fcller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PloS One"},{"issue":"11","key":"10.1053\/j.semperi.2019.05.011_bib0004","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","volume":"122","author":"Kurihara","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0005","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"issue":"22","key":"10.1053\/j.semperi.2019.05.011_bib0006","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1053\/j.semperi.2019.05.011_bib0007","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"5","key":"10.1053\/j.semperi.2019.05.011_bib0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of Type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1053\/j.semperi.2019.05.011_bib0009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.semperi.2019.05.011_bib0010","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0011","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran","year":"2014","journal-title":"Acta Ophthalmologica"},{"issue":"2","key":"10.1053\/j.semperi.2019.05.011_bib0012","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 Years of treatment of Type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for Type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0014","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1053\/j.semperi.2019.05.011_bib0015","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1053\/j.semperi.2019.05.011_bib0016","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"issue":"3","key":"10.1053\/j.semperi.2019.05.011_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0018","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1053\/j.semperi.2019.05.011_bib0019","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0020","first-page":"34","article-title":"Sedation protocol during bevacizumab intravitreal injection in preterm infants with retinopathy of prematurity","volume":"23","author":"Miller","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.semperi.2019.05.011_bib0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaapos.2017.12.005","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"Morrison","year":"2018","journal-title":"J AAPOS"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0022","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaapos.2017.06.024","article-title":"Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study","volume":"21","author":"Clark","year":"2017","journal-title":"J AAPOS"},{"issue":"3","key":"10.1053\/j.semperi.2019.05.011_bib0023","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","article-title":"Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity","volume":"125","author":"Vogel","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00417-018-4162-y","article-title":"Foveal microvascular anomalies on optical coherence tomography angiography and the correlation with foveal thickness and visual acuity in retinopathy of prematurity","volume":"257","author":"Chen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1053\/j.semperi.2019.05.011_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular Structures, Optical components and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1053\/j.semperi.2019.05.011_bib0026","first-page":"135","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"issue":"11","key":"10.1053\/j.semperi.2019.05.011_bib0027","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1053\/j.semperi.2019.05.011_bib0028","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1053\/j.semperi.2019.05.011_bib0029","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1053\/j.semperi.2019.05.011_bib0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1053\/j.semperi.2019.05.011_bib0032","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1053\/j.semperi.2019.05.011_bib0033","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1053\/j.semperi.2019.05.011_bib0034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exer.2018.01.020","article-title":"The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study","volume":"169","author":"Khalili","year":"2018","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1053\/j.semperi.2019.05.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.semperi.2019.05.011_bib0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"issue":"6","key":"10.1053\/j.semperi.2019.05.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"}],"container-title":["Seminars in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000519300710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000519300710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:55:08Z","timestamp":1758938108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146000519300710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0146000519300710"],"URL":"https:\/\/doi.org\/10.1053\/j.semperi.2019.05.011","relation":{},"ISSN":["0146-0005"],"issn-type":[{"value":"0146-0005","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Seminars in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semperi.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}